Adamis Receives FDA Approval For 505(b)(2) Naloxone
Company Has Partnered With US WorldMeds To Launch Zimhi In Q1 2022
Adamis has announced receiving FDA approval for Zimhi, its high-dose naloxone hydrochloride for injection, indicated for the treatment of opioid overdose. The company has partnered with US WorldMeds to market Zimhi by the first quarter of 2022.
You may also be interested in...
US rivals to Narcan will face obstacles as they attempt to compete in the public interest market, Emergent’s CEO told the virtual J.P. Morgan Healthcare Conference.
Teva has delivered the launch of the first generic rival to Narcan naloxone 4mg nasal spray in the US. Sandoz has immediately responded with the introduction of an authorized generic.
Keeping Track: US FDA Clears Opioid Seglentis And Anti-Opioid Zimhi; CRLs For Revance, United; Delay For UCB
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker